Clinical Trial Update: Co-administration of Olodaterol Respimat® and Tiotropium Handihaler® [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating the co-administration of olodaterol (Striverdi Respimat) and tiotropium (Spiriva HandiHaler) in chronic obstructive pulmonary disease…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• SPIRIVA HANDIHALER (TIOTROPIUM BROMIDE)
• Striverdi Respimat (olodaterol)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 3 | Status: COMPLETED | Results posted: 2014-09-04